HIV-1 Proviral Sequence and Treatment Outcome of Virologically Suppressed Patients Switching to Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (vol 79, pg e45, 2018)

被引：0
|
作者：
Andreatta, K.
Chang, S.
Martin, R.
Acosta, R.
Daeumer, M.
Thielen, A.
Miller, M. D.
White, K. L.
机构：
来源：
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2018年 / 79卷 / 04期
关键词：
D O I：
10.1097/QAI.0000000000001892
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：E111 / E111
页数：1
相关论文
共 50 条
  • [1] HIV-1 Proviral Sequence and Treatment Outcome of Virologically Suppressed Patients Switching to Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate
    Andreatta, Kristen
    Chang, Silvia
    Martin, Ross
    Acosta, Rima
    Daeumer, Martin
    Thielen, Alexander
    Miller, Michael D.
    White, Kirsten L.
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2018, 79 (01) : E47 - E51
  • [2] Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet for HIV-1 Infection Treatment
    Olin, Jacqueline L.
    Spooner, Linda M.
    Klibanov, Olga M.
    [J]. ANNALS OF PHARMACOTHERAPY, 2012, 46 (12) : 1671 - 1677
  • [3] Stribild® (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate): A New Paradigm for HIV-1 Treatment
    Manzardo, Christian
    Gatell, Jose M.
    [J]. AIDS REVIEWS, 2014, 16 (01) : 35 - 42
  • [4] Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine
    Cid-Silva, Purificacion
    Fernandez-Bargiela, Noelia
    Margusino-Framinan, Luis
    Balboa-Barreiro, Vanesa
    Mena-De-Cea, Alvaro
    Lopez-Calvo, Soledad
    Vazquez-Rodriguez, Pilar
    Martin-Herranz, Isabel
    Miguez-Rey, Enrique
    Poveda, Eva
    Castro-Iglesias, Angeles
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2019, 124 (04) : 479 - 490
  • [5] A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results
    Zolopa, Andrew
    Sax, Paul E.
    DeJesus, Edwin
    Mills, Anthony
    Cohen, Calvin
    Wohl, David
    Gallant, Joel E.
    Liu, Hui C.
    Plummer, Andrew
    White, Kirsten L.
    Cheng, Andrew K.
    Rhee, Martin S.
    Szwarcberg, Javier
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2013, 63 (01) : 96 - 100
  • [6] Switching From Twice-Daily Raltegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine to Once-Daily Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed, HIV-1-Infected Subjects: 48 Weeks Data
    Mills, A.
    Crofoot, G.
    Ortiz, R.
    Rashbaum, B.
    Towner, W.
    Ward, D.
    Brinson, C.
    Kulkarni, R.
    Garner, W.
    Ebrahimi, R.
    Cao, H.
    Cheng, A.
    Szwarcberg, J.
    [J]. HIV CLINICAL TRIALS, 2014, 15 (02): : 51 - 56
  • [7] SAFETY AND EFFICACY OF ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE IN TREATMENT-NAIVE JAPANESE PATIENTS WITH HIV-1 INFECTION
    Yajima, K.
    Yagura, H.
    Yukawa, S.
    Hirota, K.
    Ikuma, M.
    Kasai, D.
    Watanabe, D.
    Nishida, Y.
    Uehira, T.
    Shirasaka, T.
    [J]. SEXUALLY TRANSMITTED INFECTIONS, 2015, 91 : A237 - A237
  • [8] A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results
    Wohl, David
    Oka, Shinichi
    Clumeck, Nathan
    Clarke, Amanda
    Brinson, Cynthia
    Stephens, Jeffrey
    Tashima, Karen
    Arribas, Jose R.
    Rashbaum, Bruce
    Cheret, Antoine
    Brunetta, Jason
    Mussini, Cristina
    Tebas, Pablo
    Sax, Paul E.
    Cheng, Andrew
    Zhong, Lijie
    Callebaut, Christian
    Das, Moupali
    Fordyce, Marshall
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 72 (01) : 58 - 64
  • [9] Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study
    Baldin, G.
    Ciccullo, A.
    Capetti, A.
    Rusconi, S.
    Sterrantino, G.
    Cossu, M. V.
    Giacomelli, A.
    Lagi, F.
    Latini, A.
    Bagella, P.
    De Luca, A.
    Di Giambenedetto, S.
    Madeddu, G.
    [J]. HIV MEDICINE, 2019, 20 (02) : 164 - 168
  • [10] Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results
    Arribas, Jose R.
    Thompson, Melanie
    Sax, Paul E.
    Haas, Bernhard
    McDonald, Cheryl
    Wohl, David A.
    DeJesus, Edwin
    Clarke, Amanda E.
    Guo, Susan
    Wang, Hui
    Callebaut, Christian
    Plummer, Andrew
    Cheng, Andrew
    Das, Moupali
    McCallister, Scott
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017, 75 (02) : 211 - 218
12345